Ulcerative Colitis

Tofacitinib was evaluated for the expansion of its indication based on data from 3 clinical trials.

This morning, Protagonist Therapeutics announced that the Phase 2b PROPEL study of PTG-100 in patients with ulcerative colitis has been discontinued.

Takeda released new real-world data evaluating the comparative effectiveness of Entyvio (vedolizumab) and TNFα-antagonist in patients with moderately to severely active ulcerative colitis or Crohn’s disease.

Trulance is the only treatment thought to replicate the pH-sensitive activity of uroguanylin.

This morning, Novartis announced that the U.S. FDA has accepted its Biologics License Application for the proposed biosimilar adalimumab to the reference medicine, Humira, developed by AbbVie, Inc.

Disease prevalence has plateaued in the industrialized world, but is accelerating in developing nations.

Eluxadoline — a twice daily, oral medication used to treat adults with IBS-D — is a mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist.

Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.

European officials approved new biosimilar for select inflammatory diseases.

Patients with preoperative colorectal cancer have reported high incidence rates of C. difficile.

Researchers explore whether FMT is safe for children with IBD.

People with Crohn's disease can also suffer from severe joint pain.

New trial tests efficacy of CanChew Plus cannabidiol gum to treat IBS.

HOST-G904 showed positive results for treating severe bowel conditions.